{"id":7414,"date":"2021-01-11T00:00:00","date_gmt":"2021-01-11T00:00:00","guid":{"rendered":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/2021\/01\/11\/hydroxychloroquine-level-tied-to-thrombosis-risk-in-lupus\/"},"modified":"2021-01-12T18:10:22","modified_gmt":"2021-01-12T18:10:22","slug":"hydroxychloroquine-level-tied-to-thrombosis-risk-in-lupus","status":"publish","type":"post","link":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/2021\/01\/11\/hydroxychloroquine-level-tied-to-thrombosis-risk-in-lupus\/","title":{"rendered":"Hydroxychloroquine Level Tied to Thrombosis Risk in Lupus"},"content":{"rendered":"<h3>\n<p>Rate of thrombotic events lower for patients with mean HCQ blood levels &gt;1,068 versus &lt;648 ng\/mL<\/p>\n<\/h3>\n<p><b><\/b><\/p>\n<p><b><\/b><\/p>\n<p>MONDAY, Jan. 11, 2021 (HealthDay News) &#8212; For patients with systemic lupus erythematosus (SLE), lower hydroxychloroquine (HCQ) blood levels are associated with a higher risk for thrombotic events, according to a study published online Jan. 5 in <em>Arthritis &#038; Rheumatology<\/em>.<\/p>\n<p>Michelle Petri, M.D., M.P.H., from the Johns Hopkins University School of Medicine in Baltimore, and colleagues examined HCQ blood monitoring in predicting thrombosis risk in a longitudinal SLE cohort. Mean HCQ blood levels were compared for patients with and without thrombosis; the association between rates of thrombosis and HCQ blood level was examined.<\/p>\n<p>The researchers found that thrombosis occurred in 5.1 percent of the 739 patients with SLE. A lower mean HCQ blood level was seen in those with versus without thrombosis (720 \u00c2\u00b1 489 versus 935 \u00c2\u00b1 580). Thrombosis rates were reduced for every 200-ng\/mL increase in the most recent HCQ blood level and for mean HCQ blood level (rate ratios [95 percent confidence intervals], 0.87 [0.78 to 0.98; P = 0.025] and 0.87 [0.76 to 1.00; P = 0.056], respectively). Patients with mean HCQ blood levels >1,068 versus <648 ng\/mL had a reduction in thrombotic events (rate ratio, 0.31; 95 percent confidence interval, 0.11 to 0.86; P = 0.024); the significant association persisted after adjustment for confounders (rate ratio, 0.34; 95 percent confidence interval, 0.12 to 0.94; P = 0.037).<\/p>\n<p>&#8220;Empirical hydroxychloroquine dose reduction to less than 5 mg\/kg might reduce or eliminate the benefit of hydroxychloroquine in thrombosis prevention,&#8221; the authors write. &#8220;Routine clinical integration of hydroxychloroquine blood level measurement offers an opportunity for personalized drug dosing and risk management beyond rigid empirical dosing recommendations in patients with SLE.&#8221;<\/p>\n<p><a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.41621\" target=\"_blank\" rel=\"noopener\">Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n<p><i><\/i><\/p>\n<p><i>Copyright \u00a9 2020 <a href=\"http:\/\/www.healthday.com\/\" target=\"_new\" rel=\"noopener\">HealthDay<\/a>. All rights reserved.<\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Rate of thrombotic events lower for patients with mean HCQ blood levels &gt;1,068 versus &lt;648 ng\/mL<\/p>\n","protected":false},"author":4,"featured_media":7615,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[85],"tags":[186,203,125],"acf":[],"_links":{"self":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts\/7414"}],"collection":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/comments?post=7414"}],"version-history":[{"count":0,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts\/7414\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/media\/7615"}],"wp:attachment":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/media?parent=7414"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/categories?post=7414"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/tags?post=7414"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}